Study implicates another gene in the brain that causes weight gain
Mutations in a gene called OTP cause obesity by controlling the output of another gene already targeted by an anti-obesity drug, a study led by UT Southwestern Medical Center researchers shows. The ...
Forbes16d
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.
Newsweek21d
Kessler Syndrome: How Our Own Satellites Could Trap Humans on Earth
The issue has also sparked discussion of a phenomenon known as Kessler syndrome. Kessler syndrome is a hypothetical scenario proposed by NASA scientist Donald J. Kessler in 1978, predicting what ...
USA Today21d
What is the Kessler Syndrome? How space junk has become an orbital threat
All of this debris floating around in space could lead to a theoretical scenario known as the Kessler Syndrome. Here's what to know about space junk, why it's a problem and what's being done about it.
CNN21d
What is ‘Kessler Syndrome’ — and why do some scientists think the space disaster scenario has already started?
The event Reddy referred to is a hypothetical phenomenon called Kessler Syndrome. Named for American astrophysicist Donald Kessler and based on his 1978 academic paper, Kessler Syndrome — as the ...
People23d
The Surprising Reason You Can’t Keep the Weight Off
Getty And the propensity towards obesity is happening on a molecular level, as Professor Ferdinand von Meyenn, a senior author on the study at the Federal Institute of Technology in Zurich ...
The Indian Express28d
WHO scientists endorse weight loss drugs for controlling obesity: What does it mean for therapies?
In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar ...
Medscape29d
Is Oral XEN-D0501 the Next Obesity Drug Hype?
XEN-D0501, a transient receptor potential vanilloid 1 (TRPV1) antagonist, is gaining attention for its potential as an oral tablet to treat type 2 diabetes, obesity, and cardiovascular diseases.
Reuters29d
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
ScienceAlert29d
US Obesity Rates Decline For The First Time in More Than a Decade
The numbers showed that both average body mass index (BMI) and obesity rates across the population fell in 2023, having risen steadily since 2013 before leveling in 2022. While we don't yet have any ...
BioPharma Dive29d
Novo’s next-gen obesity drug misses expectations in closely watched trial
A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to lose nearly a fifth of their value ...